New clinical data has shown positive proof-of-concept results for OD-001 in a Phase 2a trial focusing on treating moderate to severe cases of ulcerative colitis. This promising development showcases the effectiveness of OD-001 as a monotherapy in addressing the condition. The specific numbers regarding the success rates and improvements observed in patients have not been disclosed.